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Abstract—Tumor necrosis factor (TNF) is the prototypic pro-
inﬂammatory cytokine. It is central to host defense and
inﬂammatory responses but under certain circumstances
also triggers cell death and tissue degeneration. Its pleiotro-
pic eﬀects often lead to opposing outcomes during the
development of immune-mediated diseases, particularly
those aﬀecting the central nervous system (CNS). The
reported contradictions may result from lack of precision
in discussing TNF. TNF signaling comprises at minimum a
two-ligand (soluble and transmembrane TNF) and two-
receptor (TNFR1 and TNFR2) system, with ligands and
receptors both diﬀerentially expressed and regulated on dif-
ferent cell types. The ‘‘functional multiplicity’’ this engen-
ders is the focus of much research, but there is still no
general consensus on functional outcomes of TNF signaling
in general, let alone in the CNS. In this review, evidence
showing the eﬀects of TNF in the CNS under physiological
and pathophysiological conditions is placed in the context
of major advances in understanding of the cellular and
molecular mechanisms that govern TNF function in general.
Thus the roles of TNF signaling in the CNS shift from the
conventional dichotomy of beneﬁcial and deleterious, that
mainly explain eﬀects under pathological conditions, to
incorporate a growing number of ‘‘essential’’ and ‘‘desir-
able’’ roles for TNF and its main cellular source in the
CNS, microglia, under physiological conditions including
regulation of neuronal activity and maintenance of myelin.
An improved holistic view of TNF function in the CNS might
better reconcile the expansive experimental data with stark
clinical evidence that reduced functioning of TNF and its
dominant pro-inﬂammatory receptor, TNFR1, are risk factors
for the development of multiple sclerosis. It will also facili-
tate the safe translation of basic research ﬁndings from ani-
mal models to humans and propel the development of more
selective anti-TNF therapies aimed at selectively inhibitinghttp://dx.doi.org/10.1016/j.neuroscience.2015.06.038
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INTRODUCTION
At the grand age of thirty since its isolation and cloning,
tumor necrosis factor (TNF, originally cachectin or TNF-
a) (Pennica et al., 1984; Wang et al., 1985; Aggarwal
et al., 1985) is the name-giving cytokine to a large ligand
superfamily and maintains its position as one of the most
intensively studied molecules in the ﬁeld of biomedical
research. It was originally identiﬁed as a blood factor
causing hemorrhagic necrosis of certain tumors
(Carswell et al., 1975; Ruﬀ and Giﬀord, 1981) and a
macrophage factor responsible for disease-associated
wasting and lethal shock (Rouzer and Cerami, 1980;
Kawakami and Cerami, 1981; Beutler et al., 1985).
Intensive multidisciplinary research into the biological
functions and therapeutic applications of TNF has
revealed ﬁne details of its functional multiplicity and com-
plexity of action. Its functions in the central nervousons.org/licenses/by-nc-nd/4.0/).
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and this represents one important limitation for the safe
therapeutic targeting of TNF in human disease.
TNF is primarily an innate immune defense molecule
important in the maintenance of homeostasis at the
cellular, tissue and organism levels (Vassalli, 1992).
Studies in mice showed that it is not necessary for normal
development but is required for proper lymphoid organ
organization and function and for host defense responses
against pathogens (Pasparakis et al., 1996), (Marino
et al., 1997). It is rapidly produced in response to stimuli,
mainly by activated macrophages and monocytes, and
also by many other cell types, and orchestrates an inﬂam-
matory response that is central to successful innate
immune responses ultimately clearing pathogens and ini-
tiating healing processes. The potent pro-inﬂammatory
properties of TNF require that its production and activity
be kept under tight temporal and spatial control. As we will
see in more detail below, multiple checkpoints are in place
to ensure that the eﬀects of TNF are limited to acute
responses, including regulation of Tnf gene expression
at transcriptional and translational levels, and the regu-
lated shedding of TNF (Black, 2004; Mohammed et al.,
2004) and its receptors (Porteu and Hieblot, 1994) in
response to various agonists. Elaborate control mecha-
nisms also operate at the level of TNF receptor signaling
so that TNF receptor 1 (TNFR1), which signals most
TNF’s eﬀects including inﬂammation and cell death,
induces pathways that appear to be hierarchically layered
to control cell fate after ligand binding, with induction of
gene transcription and pro-survival pathways through
NF-jB transcriptional activity protecting against apopto-
sis, and caspases in turn protecting against necrosis.
Disturbances at any point in the delicate web of control
mechanisms governing TNF function caused by environ-
mental or genetic factors can result in pathology. This is
aptly demonstrated at the clinical level by the TNFR1-
associated periodic syndromes (TRAPS), which are
caused by TNFR1 mutations that reduce receptor cleav-
age resulting in increased TNF signaling and systemic
autoinﬂammatory pathology (McDermott et al., 1999), as
well as cases of CNS involvement (Minden et al., 2004).
TNF is the prototypic pro-inﬂammatory cytokine. Soon
after its discovery, aberrant TNF production was found to
trigger inﬂammatory pathologies such as rheumatoid
arthritis, insulitis and inﬂammatory bowel disease in
experimental animals (Keﬀer et al., 1991; Picarella
et al., 1993; Kontoyiannis et al., 1999), and to be a char-
acteristic of diverse diseases in the periphery and CNS of
humans that involve inﬂammation, including sepsis,
chronic immune and autoimmune pathologies, neurode-
generation and cancer (Vassalli, 1992). It was quickly rec-
ognized as an important therapeutic target, and today
TNF inhibitors represent blockbuster drugs for the treat-
ment of a variety of chronic immune diseases in the
periphery, notably rheumatoid arthritis, psoriasis and
inﬂammatory bowel disease. However, shadowing the
spectacular success of non-selective TNF inhibitors are
serious side eﬀects associated with immune suppression,
especially increased risk of infections; tuberculosis, bac-
terial sepsis and invasive fungal infections; as well as oflymphoma and other malignancies in children and adoles-
cents (Kontermann et al., 2009). Entirely unexpected at
the time, was the ﬁnding that TNF inhibitors exacerbated
multiple sclerosis (MS), a common inﬂammatory demyeli-
nating disease of the central nervous system (CNS), when
tested in clinical trials in MS patients (van Oosten et al.,
1996; Multiple Sclerosis Study Group, 1999), and even
induced new cases of demyelinating disease and neu-
ropathies in patients treated for other diseases (Stubgen,
2008; Bosch et al., 2011). These clinical data provided
the ﬁrst and most convincing evidence that TNF, further
to having pro-inﬂammatory eﬀects, exerts essential bene-
ﬁcial functions in the CNS and that such eﬀects would
need to be understood and taken into consideration so that
safer TNF-targeted therapies could be developed, and if
possible applied to inﬂammatory CNS diseases.TNF AND TNF RECEPTORS
The pleiotropic eﬀects of TNF reﬂect its complex signaling
mechanisms, which are the subject of excellent reviews
and will not be detailed here (Wallach et al., 1999;
Wajant et al., 2003; Vanden Berghe et al., 2014). TNF
is produced in two bioactive forms: transmembrane TNF
(tmTNF), which acts by cell-to-cell contact, and soluble
TNF (solTNF), which is released following regulated
cleavage of tmTNF (Kriegler et al., 1988) by TNFa-
converting enzyme (TACE/ADAM17) (Black et al., 1997;
Moss et al., 1997). Studies in transgenic mice have been
instrumental for deﬁning essential functions of TNF and
its receptors in health and disease (Table 1). They
showed that tmTNF and solTNF have distinct functions
with tmTNF mediating a subset of beneﬁcial TNF activi-
ties while lacking the systemic inﬂammatory eﬀects of
solTNF. Mice deﬁcient in TNF, which are therefore deﬁ-
cient in both solTNF and tmTNF, lack normal secondary
lymphoid organ structure, fail to form germinal centers
upon immunization and are unable to mount host defense
responses to infections (Pasparakis et al., 1996; Marino
et al., 1997), or optimal inﬂammatory responses in models
of autoimmunity such as experimental autoimmune
encephalomyelitis (EAE) (Korner et al., 1997b), a
widely-used model for immune pathology in MS. By con-
trast, mice deﬁcient in solTNF, but producing functional
uncleavable tmTNF, show partially restored lymphoid
organ structure and function (Ruuls et al., 2001;
Alexopoulou et al., 2006), control Leishmania major infec-
tion (Allenbach et al., 2008) and partially control intracel-
lular bacterial infections (Torres et al., 2005;
Alexopoulou et al., 2006; Musicki et al., 2006; Olleros
et al., 2012), suggesting that tmTNF is suﬃcient for basic
host defense responses, while solTNF is necessary for
optimizing them. Importantly, tmTNF was not suﬃcient
for the development of the inﬂammatory responses nec-
essary for EAE and a model of arthritis to develop
(Ruuls et al., 2001; Alexopoulou et al., 2006). These early
ﬁndings were the ﬁrst to support the hypothesis that
selective targeting of solTNF might oﬀer signiﬁcant
advantages over non-selective blockade of TNF for the
treatment of chronic inﬂammatory diseases including
those in the CNS, by inhibiting overt inﬂammation while
Table 1. Main characteristics and CNS eﬀects of mice with targeted deﬁciencies in TNF and TNF receptors
Murine gene disrupted Main characteristics References
Tnf deletion Deﬁcient in solTNF & tmTNF
- Resistance to LPS-induced shock; increased susceptibility to infections with Listeria
monocytogenes and Candida albicans; lack splenic primary B cell follicles; cannot form fol-
licular dendritic cell networks and germinal centres
Pasparakis et al. (1996)
Marino et al. (1997)
- Reduced OPC and remyelination in MS model Arnett et al. (2001)
- Increased lesions in cerebral ischemia model Lambertsen et al. (2009)
- Delayed EAE onset & lymphocyte inﬁltration of CNS, enhanced severity of chronic disease Korner et al. (1997a,b)
Frei et al. (1997)
Liu et al. (1998)
Kassiotis and Kollias (2001)
Tnf D1–9 K11E
(uncleavable
tmTNF knockin)
Deﬁcient in solTNF
- Resistance to LPS-induced shock; improved lymphoid organ structure compared to Tnf
deletion; resistance to EAE
Ruuls et al. (2001)
Tnf D1–12
(uncleavable
tmTNF knockin)
Deﬁcient in solTNF
- Resistance to LPS-induced shock; like Tnf/ mice, lack splenic primary B cell follicles;
cannot form follicular dendritic cell networks and germinal centres.; resistance to Listeria
monocytogenes; resistance in arthritis and EAE models
Alexopoulou et al. (2006)
Tnfrsf1a deletion Deﬁcient in TNFRI
- Resistance to LPS-induced shock; increased susceptibility to Listeria monocytogenes;
resistance to lethal LPS doses
Rothe et al. (1993)
Pfeﬀer et al. (1993)
- Increased lesions in cerebral ischemia model Gary et al. (1998)
Taouﬁk et al. (2007)
- Increased hippocampal neuron death in epilepsy model Lambertsen et al. (2009)
- Reduced pathology in retinal ischemia and AD models Fontaine et al. (2002)
He et al. (2007)
- Delayed EAE onset Suvannavejh et al. (2000)
Eugster et al. (1999)
Kassiotis and Kollias (2001)
Tnfrsf1b deletion Deﬁcient in TNFRII
- Increased serum TNF; increased resistance to TNF-induced cell death and tissue necrosis Erickson et al. (1994)
Peschon et al. (1998)
- Reduced OPC proliferation and remyelination in MS model Arnett et al. (2001)
- Increased sensitivity of cortical neurons to glutamate excitotoxicity in vitro and increased
pathology in retinal ischemia model in vivo
Marchetti et al. (2004)
Fontaine et al. (2002)
- Increased EAE severity Eugster et al. (1999)
4 L. Probert / Neuroscience 302 (2015) 2–22maintaining host defense and possibly other beneﬁcial
mechanisms.
Additional layers of complexity are present at the level
of intracellular TNF signaling. TNF signals through two
distinct cell-surface high-aﬃnity receptors, TNFR1
(CD120a, 55 kDa; encoded by TNFRSF1A) and TNFR2
(CD120b, 75 kDa; encoded by TNFRSF1B), which are
the founding members of the TNFR superfamily. tmTNF
signals eﬃciently through TNFR1 and 2, while solTNF
selectively signals through TNFR1, leaving tmTNF as
the main TNFR2 ligand (Grell et al., 1995). TNFR1 is
ubiquitously and constitutively expressed and shows
highly complex signaling pathways. Brieﬂy, TNFR1
engagement leads to the recruitment of TRADD
(TNFR1-associated death domain protein), which acts
as a platform for various signaling complexes that are
involved in two diametrically opposed outcomes; cell sur-
vival and death. TNFR1 is a member of the death receptor
family (DR) because it has an intracellular death domain
sequence and can induce apoptosis in sensitized cells
by the recruitment of FADD (Fas-associated death
domain protein) and caspase 8 to TRADD through homo-
typic death domain interactions (Wallach et al., 1999;
Wilson et al., 2009). However, TNFR1 is not cytotoxic to
most cells and induces direct pro-inﬂammatory signalingthrough the formation of a membrane-associated protein
complex (complex I). Here, TRADD recruits TRAF2
(TNFR-associated factor 2), RIP-1 (receptor-interacting
protein-1), cellular inhibitor of apoptosis protein-1 or -2
(cIAP-1, cIAP-2) and LUBAC (linear ubiquitin chain
assembly complex), and favors activation of proinﬂamma-
tory signals through the transcription factors NF-jB and
AP-1 (Micheau and Tschopp, 2003; Walczak, 2011).
NF-jB induces transcription of many genes including
those encoding proinﬂammatory cytokines, chemokines
and antiapoptotic factors such as cIAP1/2, Bcl-2, Bcl-xL
and c-FLIP (cellular FLICE-inhibitory protein)(Wajant
et al., 2003). Activation of NF-jB is therefore a primary
mechanism of cell protection against death stimuli; the
switch to cell death follows destabilization of complex I,
e.g. by blockade of protein synthesis or of NF-jB activity
(Baud and Karin, 2001; Karin and Lin, 2002) and forma-
tion of a cytosolic complex II which signals cell death
(Wallach et al., 1999; Micheau and Tschopp, 2003). In
line with the primary role of TNF as a defense molecule,
TNFR1 controls defense at the cellular level, by inducing
death of damaged, infected cells, at the tissue level by
orchestration of the inﬂammatory response, and at the
organism level by inducing changes such as fever and
sleep. Indeed, similar to TNF knockout mice deﬁcient in
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tmTNF knockin mice deﬁcient only in solTNF (Ruuls
et al., 2001; Alexopoulou et al., 2006), TNFR1 knockout
mice show reduced inﬂammatory responses. Also, similar
to TNF knockout mice (Pasparakis et al., 1996), but unlike
tmTNF knockin mice (Ruuls et al., 2001; Alexopoulou
et al., 2006), TNFR1 knockout mice show reduced
defense against the intracellular pathogen Listeria mono-
cytogenes (Pfeﬀer et al., 1993; Rothe et al., 1993).
Together, these data show that solTNF and TNFR1 are
necessary for inﬂammation while tmTNF and TNFR1
are critical for anti-Listerial defense.
By contrast to the widely expressed TNFR1, TNFR2
expression is restricted to immune cells, endothelial
cells, and several CNS cell types (see below), and
fewer independent activities have been identiﬁed.
TNFR2 lacks a death domain and mainly activates pro-
survival signals by direct recruitment of TRAF2 and
subsequent activation of PKB/Akt and NF-jB pathways
(Medvedev et al., 1994; Rao et al., 1995). These proper-
ties, coupled with its activation by both tmTNF and
solTNF (Grell et al., 1995), and the ﬁnding that TNFR2-
deﬁcient mice have increased levels of serum solTNF in
response to lipopolysaccharide (LPS) injection and exac-
erbated TNFR1-mediated inﬂammation (Erickson et al.,
1994; Peschon et al., 1998), suggest it is more likely to
play a role in speciﬁc local homeostatic processes and
possibly the reinforcement of TNFR1-mediated
responses, although it is likely that further unique func-
tions for this receptor will be discovered.Fig. 1. Diagrammatic representation of the main cellular sources, molecular f
pathological conditions. Under physiological conditions (yellow) and during h
activity in microglia (MG), neurons (N) and astrocytes (AST) and is importan
also constitutively express TNFR1 and TNFR2, which are important for media
(OLG) and OPC express TNFR2, which is necessary for OPC proliferatio
neurodegeneration (pink), the primary disease trigger activates microglia
‘‘neuroinﬂammatory unit’’ and secondary tissue damage together with inﬁltrat
(MF), neutrophils (N) as well as CD4+(Th1, Th17) and CD8+(Tc1) lymphoc
and ICAM by endothelial cells (EC).EARLY STUDIES OF TNF IN THE CNS
In general, TNF plays a prominent role in the induction
and maintenance of inﬂammation including that in the
CNS (Fig. 1). Elevated production of TNF is evident in
patients and animal models of a wide range of CNS
pathologies including chronic diseases such as MS
(Hofman et al., 1989; Sharief and Hentges, 1991;
Selmaj et al., 1991a), Alzheimer’s disease (AD) (Fillit
et al., 1991; Paganelli et al., 2002), Parkinson’s disease
(PD) (Boka et al., 1994; Mogi et al., 1994, 2000), HIV
encephalopathy (Grimaldi et al., 1991) and meningitis
(Leist et al., 1988) as well as following acute injuries such
as cerebral stroke (Liu et al., 1994; Barone et al., 1997)
and trauma (Ross et al., 1994; Gourin and Shackford,
1997). In the mouse, circulating TNF has been shown to
cross the BBB into the brain via a speciﬁc saturable trans-
port system (Gutierrez et al., 1993). TNF is also produced
constitutively in the CNS by several populations of neu-
rons (Breder et al., 1993). Inﬂammatory stimuli such as
LPS and cytokines induce TNF production by additional
CNS cell types, particularly microglia which are a rich
source of TNF (Sawada et al., 1989), astrocytes
(Lieberman et al., 1989; Chung and Benveniste, 1990)
and ependymal cells of the choroid plexus (Tarlow
et al., 1993). Under conditions of pathology, such as
experimental cerebral ischemia, TNF is also expressed
by injured neurons and inﬁltrating immune cells (Liu
et al., 1994; Botchkina et al., 1997).
There is a large body of evidence that TNF is a key
mediator of secondary CNS damage following acuteorms and receptor targets of TNF in the CNS under physiological and
ost defense responses (green), TNF expression is induced by basal
t for regulating neuronal function, including synaptic activity. Neurons
ting neuroprotection against neurotoxic stimuli, while oligodendrocytes
n and myelin repair. Under conditions of autoimmunity or chronic
to chronically produce high levels of solTNF, resulting in a local
ion of CNS tissues by peripheral immune cells such as macrophages
ytes following the upregulation of adhesion molecules such as VCAM
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Intracerebral administration of TNF 24 h before the
induction of transient or permanent experimental
ischemia exacerbated neurological defects and lesion
size, and these eﬀects were reversed by co-
administration of a neutralizing anti-TNF antibody
(Barone et al., 1997). TNF induces leukocyte adhesion
to cerebral vessels through the upregulation of adhesion
molecules such as VCAM and ICAM (Pober and Cotran,
1990) and can contribute to blood–brain barrier (BBB) dis-
ruption (de Vries et al., 1996). Soluble human TNF, which
signals eﬃciently through mouse TNFR1, not TNFR2
(Lewis et al., 1991), also induced delayed-onset oligoden-
drocyte necrosis and dilation of myelin when administered
to myelinated cultures of mouse spinal cord tissue
(Selmaj and Raine, 1988), indicating a cytotoxic eﬀect of
TNF/TNFR1 signaling on oligodendrocytes that has direct
implications for the pathogenesis of demyelinating dis-
eases. Consistent with this, transgenic mice that overex-
press human or mouse TNF transgenes from CNS glia
induced oligodendrocyte apoptosis, neuroinﬂammation
and the development of demyelinating lesions similar to
those seen in MS (Probert et al., 1995; Akassoglou
et al., 1997, 1998) and enhanced severity of EAE, an ani-
mal model for MS induced by immunization with myelin
auto-antigens (Taupin et al., 1997). Local CNS production
of TNF was responsible for the exacerbated EAE pathol-
ogy seen in mice deﬁcient in cytokine ciliary neurotrophic
factor (CNTF), a survival factor for neurons and oligoden-
drocytes, because disease increase was prevented by
treatment with anti-TNF antibody (Linker et al., 2002).
Genetic studies in mice conﬁrmed the importance of
TNF in the induction phase of EAE and revealed critical
points of TNF action during disease progression that
were generally consistent across the diﬀerent strains of
mice and EAE models used (Table 1). One set of
studies showed that the onset of EAE is delayed in
TNFKO mice, which are deﬁcient in both solTNF and
tmTNF, and this was associated with altered movement
of inﬂammatory leukocytes in the CNS, eﬀects
consistent with a pro-inﬂammatory, disease-advancing
role for TNF. However, mice eventually developed the
full-blown disease (Korner et al., 1997b; Liu et al., 1998;
Kassiotis et al., 1999). Importantly, another set of studies
showed that clinical symptoms and pathology, once estab-
lished, became more severe in mice deﬁcient in solTNF,
tmTNF and lymphotoxin a (Frei et al., 1997), solTNF
and tmTNF (Liu et al., 1998) or TNFR1 (Kassiotis and
Kollias, 2001). TNFKO also converted mice of the
129/SV strain from EAE-resistance to susceptibility and
the i.v. administration of human TNF abrogated disease
in TNFKO mice (Liu et al., 1998). Collectively, these data
were among the ﬁrst to hint that TNF exerts diﬀerential
roles at diﬀerent stages of autoimmune demyelination,
with solTNF, and not tmTNF, advancing inﬂammation
and the onset of new disease, while solTNF and/or
tmTNF were protective in established disease by limiting
the extent and severity of autoimmune pathology.
Consistent with the inﬂammatory eﬀects of TNF, the
peripheral or central administration of anti-TNF
antibodies or soluble TNF receptors ameliorateddisease in a variety of experimental models involving
CNS inﬂammation including EAE induced by T cell
transfer (Ruddle et al., 1990; Selmaj et al., 1991b,
1995) or active immunization (Baker et al., 1994; Korner
et al., 1995, 1997a; Martin et al., 1995), cerebral ischemia
(Meistrell et al., 1997; Nawashiro et al., 1997; Lavine
et al., 1998) and head trauma (Shohami et al., 1996).
The failure of clinical trials in MS patients using non-
selective TNF inhibitors was therefore diﬃcult to explain
at the time. In one study, two rapidly progressing MS
patients were treated with i.v. infusion of a humanized
mouse monoclonal anti-TNF antibody in a phase I safety
trial. Treatment was associated with increased disease
activity as measured by increased gadolinium-
enhancing MRI lesions and cell and immunoglobulin con-
tent in the CSF (van Oosten et al., 1996). In a second
study, MS patients, mostly with relapsing-remitting MS
(RRMS), were treated with lenercept, a dimeric TNFR1
extracellular domain fused to a human IgG1 heavy chain
fragment that binds to both solTNF and tmTNF and inhi-
bits binding to TNFR, in a phase II placebo-controlled trial.
This trial was halted following an increase in the number
of treated patients experiencing disease exacerbations
compared to placebo and a tendency toward more severe
neurological defects (Multiple Sclerosis Study Group,
1999). These trials provided strong clinical evidence that
non-selective inhibition of TNF is not only non-beneﬁcial,
but positively deleterious in MS and that TNF, further to
its potent pro-inﬂammatory role, mediates essential pro-
tective functions in the CNS. Since then, the use of non-
selective TNF inhibitors for diseases such as rheumatoid
arthritis and Crohn’s disease has been associated with
cases of new onset or exacerbation of CNS demyelinating
disorders, as described on the safety warning labels of the
approved TNF inhibitors, etanercept, inﬂiximab, goli-
mumab, adalimumab and certolizumab, and some of
these cases are associated with changes in mental status
or permanent neurological disability (Stubgen, 2008;
Bosch et al., 2011). Collectively, these early experimental
and clinical data clearly showed that, unlike in the periph-
ery, TNF and its receptors perform both pro-inﬂammatory
eﬀects that exacerbate neuroinﬂammation and secondary
neuronal damage and protective eﬀects in the CNS under
conditions of pathophysiology.
FIRST EVIDENCE FOR PROTECTIVE EFFECTS
OF TNF IN THE CNS
Several independent lines of evidence showing beneﬁcial
functions of TNF in the CNS response to injury emerged
alongside the studies that showed its neuroinﬂammatory
eﬀects.
First, brief periods of mild ischemia and hypothermia
(Kirino et al., 1991; Kitagawa et al., 1991), or a single intra-
venous injection of LPS (Tasaki et al., 1997), induce robust
tolerance against subsequent severe ischemia, a phe-
nomenon known as ischemia preconditioning. The obser-
vation that intravenous administration of a TNF binding
protein (a recombinant type I soluble TNF receptor dimer
conjugated to polyethylene glycol), completely nulliﬁed
the preconditioning eﬀect of systemically-administered
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solTNF and tmTNF, was essential for the induction of
ischemia preconditioning. The further ﬁnding that pretreat-
ment of mice by intracisternal administration of TNF pre-
conditioned them to tolerate an otherwise damaging
ischemic insult (Nawashiro et al., 1997), showed that
solTNF is suﬃcient for initiating preconditioning tolerance
through local mechanisms in the CNS.
Second, in a model of cuprizone-induced
demyelination and remyelination, TNF-deﬁcient mice
showed delayed remyelination and a reduction in
proliferating NG2+ cells, which mainly represent
oligodendrocyte precursor cells, suggesting that TNF
plays an important role in the spontaneous remyelination
of demyelinated axons in this model (Arnett et al., 2001).
In the same study, further analysis in mice deﬁcient in
TNF receptors revealed a role for TNFR2, and therefore
tmTNF, in promoting the proliferation of oligodendrocyte
progenitors and in remyelination (Fig. 1).
Third, seminal studies by Mark Mattson and his team
to investigate the cellular basis of neuroprotection under
conditions that prevail during CNS degeneration
demonstrated that TNF is not directly toxic to primary
embryonic neurons. On the contrary, TNF pre-treatment
strongly protected hippocampal, septal and cortical
neurons against a variety of injurious stimuli including
glucose deprivation, glutamate excitotoxicity (Cheng
et al., 1994) and iron and amyloid-b peptide (Barger
et al., 1995). TNF-induced neuroprotection correlated with
attenuated elevation of stimulus-induced intracellular
Ca2+, was mimicked by the induction of NF-jB activity
and was associated with increased expression of the
calcium-binding protein calbindin-D28 k (Cheng et al.,
1994; Barger et al., 1995) and the protective antioxidant
enzyme MnSOD (Bruce et al., 1996). Interestingly,
lymphotoxin-a (TNF-b), which also signals through
TNFR1 and TNFR2, induced similar neuroprotective
eﬀects as TNF, further supporting a direct role for neu-
ronal TNFR in signaling protection. The in vivo relevance
of this mechanism was demonstrated in mice lacking both
TNFR1 and TNFR2, which showed exacerbated neuronal
damage induced by focal cerebral ischemia and kainic
acid-induced epileptic seizures compared to wild-type
controls (Bruce et al., 1996). Elegant studies by Bente
Finsen’s team using bone marrow chimeric mice later
showed that brain TNF production, rather than immune
cell TNF production, is responsible for neuroprotection fol-
lowing ischemia (Lambertsen et al., 2009).
Given that TNF has the potential to mediate multiple
eﬀects in the CNS in the context of a chronic
neurodegenerative disease ranging from glial cell and
stem cell activation and proliferation, vascular changes,
cell death, neuron survival and beneﬁcial eﬀects on
myelin, it is not surprising that the ﬁnal outcome of non-
selective TNF administration or blockade can give
apparently contrasting eﬀects across diﬀerent diseases
and between experimental models and human disease.
Below, evidence for the functions and eﬀects of TNF
and TNFR in the CNS are reviewed in the context of
knowledge of known cellular and molecular mechanisms
of TNF-TNFR signaling with the aim of reconcilingavailable ‘‘contradictory’’ data and gaining an integrated
overall view to help assess whether or not TNF can be
safely targeted for the treatment of CNS diseases.
TNF NEUROREGULATION IN THE NORMAL
CNS
Several lines of evidence show that TNF plays an
important role in controlling excitatory transmission in
the CNS under physiological conditions (Fig. 1). TNF is
constitutively expressed at low levels in the normal adult
brain (Breder et al., 1993; Vitkovic et al., 2000;
Boulanger, 2009). Seminal studies by Robert Malenka
and his team showed that TNF is important for homeo-
static synaptic scaling, a form of synaptic plasticity that
allows the adjustment of the strength of all synapses on
a neuron in response to prolonged changes in the cells
electrical activity (Stellwagen and Malenka, 2006;
Turrigiano, 2008). This process is induced by exoge-
nously administered solTNF in cultured hippocampal neu-
rons and is dependent on endogenous glia-derived
solTNF in the hippocampus (Stellwagen and Malenka,
2006) and cortex, where it plays a speciﬁc role in
experience-dependent plasticity in the developing visual
cortex (Kaneko et al., 2008). TNF strengthens glutamater-
gic synaptic transmission by inducing a rapid (10 min)
increase in surface AMPA receptor (a-amino-3-hydroxy-
5-methyl-4-isoxazole proprionic acid receptors, AMPAR)
subunits on hippocampal (Beattie et al., 2002; Ogoshi
et al., 2005; Stellwagen et al., 2005) and cortical (He
et al., 2012) neurons. The constitutive presence of
solTNF may even be essential for maintaining synaptic
function because TNF blockade reduced surface
AMPAR levels in cortical (He et al., 2012), hippocampal
(Ogoshi et al., 2005; Stellwagen et al., 2005) and motor
(Ferguson et al., 2008) neurons and decreased synaptic
strength at hippocampal synapses (Beattie et al., 2002).
Conversely, solTNF treatment reduced surface GABA
receptors on hippocampal neurons (Stellwagen et al.,
2005; Leonoudakis et al., 2008; Pribiag and Stellwagen,
2013) and TNF reduced AMPAR in inhibitory striatal neu-
rons through the preferential removal of Ca2+-permeable
AMPAR (Lewitus et al., 2014). The net eﬀect of such
changes was increased excitatory over inhibitory synaptic
transmission in hippocampal slices (Stellwagen et al.,
2005) and possibly other neuronal circuits.
TNF can also potentiate excitatory transmission by
coordinating glutamate release from astrocytes in a
process called gliotransmission. Astrocytes and
microglia are integral components of CNS synapses
where they are known to be important for sensing and
removing glutamate from the synaptic cleft, thereby
limiting the duration of synaptic excitation (Perea et al.,
2009). However, a recent study using TNF knockout mice
revealed that the constitutively present TNF in control ani-
mals is critical for controlling glutamate release from
astrocytes in response to elevations of intracellular
Ca2+, a process that potentiates excitatory synapses in
the dentate gyrus of the hippocampus through the activa-
tion of presynaptic NMDAR (Santello et al., 2011).
Exogenous administration of low picomolar amounts of
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deﬁcient astrocytes (Santello et al., 2011). Taken
together, these ﬁndings indicate that local production of
solTNF at excitatory synapses in the CNS under physio-
logical conditions is desirable for rapid neuroregulatory
eﬀects that result in strengthening of synaptic connectivity
and neuronal networks under physiological conditions
(Table 2).
THE MULTIPLICITY OF TNFR1 FUNCTION IN
THE CNS; INFLAMMATION AND CELL
SURVIVAL VERSUS APOPTOSIS VERSUS
NECRO(PTO)SIS
TNF signaling through TNFR1, which is expressed on
most cell types, mainly results in the activation of
transcription factors NF-jB and AP-1 and the
expression of genes encoding cytokines, chemokines,
anti-apoptotic and cell survival molecules (Wajant et al.,
2003). TNFR1 therefore plays a dominant role inTable 2. The main described eﬀects of TNF and its receptors in the CNS und
Eﬀects induced Ligand/recept
involved
Deleterious
Pro-inﬂammatory eﬀects that induce and further promote
acute injury, autoimmune, inﬂammatory and
neurodegenerative diseases of the CNS
solTNF, TNFR
Death of dopaminergic neurons in vitro and in vivo, retinal
ganglion cells in vivo
solTNF, TNFR
Delayed death of oligodendrocytes in vitro and in vivo solTNF, TNFR
Essential
Protection against MS in patients (non-selective TNF
inhibitors exacerbate existing and induce new human
disease).
solTNF and/o
tmTNF
Protection against neuroinﬂammation, demyelination and
neurodegeneration in mice (EAE)
tmTNF, TNFR
TNFRII
Protection of neurons against excitotoxic, metabolic and
oxidative insults in vitro
solTNF
pretreatment,
tmTNF, TNFR
TNFRII
Wild-type TNFRI protective against MS in
patients(TNFRSF1 variants, including one lacking
TNFRI intracellular domains, are MS risk factors)
TNFRI
TNFRI presence limits neuronal damage and increases
survival in acute injury models (ischemia, temporal
epilepsy)
TNFRI
Preconditioning tolerance against ischemia in mice solTNF and/o
tmTNF
Desirable
Synaptic scaling: glia-derived TNF potentiates excitatory
glutamatergic signaling by increasing neuronal surface
AMPA receptors (GluR1) and reducing GABAA
receptors
solTNF
Gliotransmission- astrocyte TNF potentiates glutamatergic
signaling by coordinating astrocyte glutamate release
solTNF and/o
tmTNF
Proliferation of oligodendrocyte precursor cells and
remyelination in cuprizone-induced demyelination
TNFRII, tmTNmediating the cell activation and pro-inﬂammatory eﬀects
of TNF (Table 2). Indeed, EAE experiments in TNFR1KO
mice showed complete resistance to disease
(Suvannavejh et al., 2000; Kassiotis and Kollias, 2001)
or a delayed onset and overall milder but progressive form
of disease compared to wild-type controls (Eugster et al.,
1999; Wheeler et al., 2006). Interestingly, resistance was
associated either with reduced (Suvannavejh et al., 2000;
Kassiotis and Kollias, 2001) or increased antigen-speciﬁc
T cell priming responses, and the accumulation of inﬂam-
matory cells in CNS tissues in the chronic phase of dis-
ease (Eugster et al., 1999), including CD4+IFN-c-
producing T cells (Wheeler et al., 2006). Unlike TNFKO
mice, which also showed a mild, progressive form of
EAE that was associated with a failed regression of T cell
responses to antigen, TNFR1KO mice showed timely
regression of antigen-speciﬁc T cell responses suggest-
ing that TNF/TNFR2 signaling might be regulating
chronicity of the autoimmune component (Kassiotis and
Kollias, 2001), possibly through induction of regulatory Ter physiological and pathophysiological conditions
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L. Probert / Neuroscience 302 (2015) 2–22 9cells (Chen et al., 2007). Further, studies using bone mar-
row chimeric mice showed that the essential TNFR1-
responsive cells for EAE induction reside in the host tis-
sue, most likely cells within the CNS (Gimenez et al.,
2006). Collectively, these data show that TNFR1 is
essential for the onset of CNS autoimmune disease,
through induction of a pro-inﬂammatory environment in
the CNS, but thereafter acts to limit the levels of local
inﬂammation possibly as an indirect consequence of neu-
roprotection or by directly promoting repair processes.
Consistent with these results, selective targeting of
TNFR1 by the prophylactic administration of an antago-
nistic mutant TNF (Nomura et al., 2010) or antagonistic
antibody (Williams et al., 2014) delayed the onset and
reduced the severity of EAE but the long-term eﬀects on
disease progression were not reported. Another natural
mechanism that may regulate the deleterious eﬀects of
TNF/TNFR1 signaling during CNS neurodegeneration
was identiﬁed in the wobbler mouse model of motor neu-
ron disease. Here TNF caused upregulation of the
metalloprotease-disintegrin ADAM8 in the wobbler CNS,
which in turn cleaved TNFR1 and mediated neuroprotec-
tion (Bartsch et al., 2010).TNFR1 PROTECTS CNS CELLS AGAINST
APOPTOSIS
As mentioned, under certain conditions that destabilize
TNFR1 complex I such as reduced anti-apoptosis
signaling through NF-jB, a cytosolic complex II is
formed consisting of TRADD, FADD (Fas-associated
death domain) and pro-forms of caspases 8 and 10 (in
humans), which signals apoptosis (Wallach et al., 1999;
Micheau and Tschopp, 2003). Procaspase 8 becomes
activated by oligomerization and autoproteolytic process-
ing on this apoptotic platform; releasing active heterote-
trameric caspase 8 into the cytoplasm, which triggers a
caspase cascade and apoptotic cell death. The NF-jB-
inducible caspase 8/10 regulator c-FLIP protein can inhibit
apoptosis by competitively dimerizing with caspase 8 and
inhibiting its activation and thereby acts as a molecular
switch between DR-induced cell death and survival
(Tschopp et al., 1998). The FADD-caspase 8 platform
can also be recruited and activated following ligand
engagement by other DR such as Fas and TRAIL recep-
tors (Peter and Krammer, 2003;Wilson et al., 2009), which
are expressed by various cells in the CNS including neu-
rons and oligodendrocytes (Nitsch et al., 2000; Dorr
et al., 2002; Ryan et al., 2004; Spierings et al., 2004).
DR-mediated apoptosis plays an important role in control-
ling neuron numbers and connectivity during development
as well as in neurodegenerative diseases such as MS and
is covered in excellent reviews (Yuan and Yankner, 2000).
Genetic studies in models of acute brain injury have
clearly shown that the physical presence of TNFR1 is
essential for neuroprotection and animal survival. Mice
deﬁcient in both TNFR1 and TNFR2 (Bruce et al., 1996),
or in TNFR1 (Gary et al., 1998; Taouﬁk et al., 2007;
Lambertsen et al., 2009), showed signiﬁcantly enhanced
tissue damage compared to wild-type controls and
TNFR2KOmice following experimental cerebral ischemia,with TNFR1KO mice also showing increased post-
ischemia mortality (Taouﬁk et al., 2007). Also, TNFR1KO
mice showed increased degeneration of CA3 hippocampal
neurons compared to wild-type and TNFR2KO mice in a
kainic acid model of temporal epilepsy (Gary et al.,
1998). In these models neuron death is mainly mediated
by excitotoxicity caused by calcium inﬂux via voltage-
dependent calcium channels and receptors for the excita-
tory amino acid neurotransmitter glutamate, particularly
the N-methyl-D-aspartate (NMDA) receptor and kainate
receptors. TNF-mediated protection of cultured cortical
and hippocampal neurons and in mice against excitotoxic,
metabolic and oxidative insults (Cheng et al., 1994; Barger
et al., 1995), was shown to involve NF-jB activation and
the transcription of gene targets including the antioxidant
enzyme manganese superoxide dismutase (Mn-SOD)
(Mattson et al., 1997), the calcium-binding protein cal-
bindin (Cheng et al., 1994), glutamate receptor subunits
(Furukawa and Mattson, 1998), anti-apoptotic proteins
such as Bcl-2 (Mattson and Camandola, 2001) and c-
FLIP (Taouﬁk et al., 2007), and receptors for other neuro-
protective factors such as erythropoietin (Taouﬁk et al.,
2008). As TNFR1 engagement is a major trigger of induci-
ble NF-jB activation and the transcription of cell survival
molecules, it is likely to play a major role in promoting neu-
ronal survival through mechanisms such as the stabiliza-
tion of calcium homeostasis and inhibition of caspase
activation and apoptosis. Indeed, we showed that neu-
ronal expression of the caspase 8 inhibitor c-FLIP was suf-
ﬁcient to protect cultured TNFR1KO cortical neurons
against apoptosis induced by glucose deprivation and
reduce lesion volume after experimental ischemia in mice
(Taouﬁk et al., 2007). Also, in the EAE model, inducible
NF-jB activity in neurons was essential for limiting clinical
deﬁcits and CNS damage during the chronic phase of dis-
ease (Emmanouil et al., 2009).
TNFR-mediated neuroprotection is not limited to
conditions of acute ischemic injury. In a mouse model
for PD, induced by peripheral injection of mitochondrial
complex 1 inhibitor 1-methyl-4-phenyl-1,2,3,6-tetrahydro
pyridine (MPTP), mice deﬁcient in both TNFR, but not
individual receptors, showed reduced dopamine levels
before and after acute MPTP intoxication compared to
controls although numbers of nigral dopaminergic
neurons were not altered (Rousselet et al., 2002). In
another study, acute MPTP intoxication increased neu-
ronal damage in the hippocampus of double TNFR-
deﬁcient mice, pointing to a combined neuroprotective
eﬀect of the two TNFR (Sriram et al., 2006). In contrast
to hippocampal neurons, dopaminergic neurons were pro-
tected against MPTP neurotoxicity in double TNFR-
deﬁcient, but not single TNFR-deﬁcient mice, an eﬀect
that was associated with reduced glial cell activation
(Sriram et al., 2002, 2006; Leng et al., 2005). The possi-
bility that TNFR1 and TNFR2 promote dopamine neuron
toxicity through combined eﬀects on neuroinﬂammation
would be consistent with growing evidence that implicates
microglia and inﬂammatory processes in the pathophysi-
ology of PD (McCoy et al., 2006; McCoy and Tansey,
2008; Hirsch and Hunot, 2009).
On the other side of the coin, while the majority of
studies point to a direct neuroprotective role for the
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and trauma, in other models TNFR1 is implicated in
severe neuronal loss. In a mouse model of retinal
ischemia, which induces ischemia–reperfusion injury
and a signiﬁcant loss of neurons from all retinal cell
layers by necrosis, TNFR1KO mice were completely
protected. Neuron survival in this model was dependent
on the activation of an Akt/phosphatidylinositol 3-kinase
signaling pathway, possibly mediated by TNFR2
(Fontaine et al., 2002). In this model, it is possible that
the pro-inﬂammatory eﬀects of solTNF/TNFR1 signaling
mask the contribution of TNF to neuroprotection, although
a direct eﬀect of TNFR1 in degeneration of retinal neurons
cannot be excluded.
In oligodendrocytes, DR including TNFR1 are
implicated in the direct induction of death in vitro and in
vivo. Oligodendrocytes express TNFR1, TNFR2 and
Fas in CNS tissues in MS and EAE (D’Souza et al.,
1996; Raine et al., 1998; Brambilla et al., 2011). Mice car-
rying natural mutations lpr and gld express inactive forms
of Fas and Fas ligand respectively and develop markedly
reduced EAE in the presence of competent immune
responses (Malipiero et al., 1997; Sabelko et al., 1997;
Waldner et al., 1997). Reduced EAE in these mice is
thought to be due to reduced oligodendrocyte death and
therefore restimulation of autoreactive T cells in vivo by
cognate antigen. Consistent with this, mice conditionally
deﬁcient in Fas (Hovelmeyer et al., 2005) or FADD (Mc
Guire et al., 2010) in oligodendrocytes showed markedly
reduced EAE accompanied by reduced demyelination
and oligodendrocyte apoptosis indicating a direct role for
Fas in the demise of oligodendrocytes and demyelination
in EAE. TNF induced oligodendrocyte and myelin damage
when applied to myelinated cultures of mouse spinal cord
(Selmaj and Raine, 1988) and mice doubly deﬁcient in
TNFR1 and oligodendrocyte-speciﬁc Fas were resistant
to EAE (Hovelmeyer et al., 2005). However, the mecha-
nism by which TNF contributes to oligodendrocyte death
remains to be established. Importantly, a series of studies
by Cedric Raine and his colleagues revealed that dying
oligodendrocytes show features of lysis rather than apop-
tosis in MS and EAE lesions (Raine et al., 1998). In fact
TNF induced ‘‘non-classical’’ apoptotic death in cultured
human oligodendrocytes that was not associated with
caspase activation, not prevented by the pan caspase
inhibitor zVAD-fmk, and was dependent on apoptosis
inducing factor (AIF), all features consistent with DR-
induced necrosis (Jurewicz et al., 2005). It remains to
be determined whether and under which conditions TNF
can further promote oligodendrocyte death by the induc-
tion of necroptosis (see below).TNFR1 PROTECTS CNS CELLS AGAINST
NECROSIS
The anti-apoptotic properties of TNFR1 signaling may
only partially explain the neuroprotective eﬀects of this
receptor in acute CNS injuries and why they fail to
protect neurons against insults such retinal ischemia–
reperfusion injury and oligodendrocytes against
immune-mediated damage in MS and EAE. Over thepast decade detailed biochemical analyses have
revealed additional complexity in TNFR1 signaling
pathways and their regulation and have revealed further
mechanisms that might contribute to the neuroprotective
properties of this receptor. A seminal paper by Peter
Brouckaert’s group tested whether caspase inhibition
would alleviate TNF toxicity in vivo. Surprisingly, pan-
caspase inhibition by administration of the protease
inhibitor zVAD-fmk in mice exacerbated TNF toxicity by
enhancing oxidative stress and mitochondrial damage
(Cauwels et al., 2003). Studies by Peter Vandenabeele
and others showed that cell death triggered by TNFR1
engagement incorporates an additional switch that deci-
des between caspase-induced apoptosis and necrosis.
Detailed biochemical studies have identiﬁed the kinases
receptor-interacting protein 1 (RIP1) and RIP3 as key sig-
naling molecules in TNF-induced programed necrosis,
named necroptosis, in which RIP3 is activated and
induces reactive oxygen species accumulation, calcium
inﬂux and lysosome destabilization leading to energy fail-
ure and death (Zhang et al., 2009; Vandenabeele et al.,
2010). The implications of these results are that TNFR1
signaling and the FADD/caspase 8 apoptotic platform rep-
resent an additional layer of protection at cellular and
organism levels that allows cells to die ‘‘decently’’ by
apoptosis, thereby avoiding inﬂammation induced by
necroptotic cell death. Pan-caspase inhibition was ﬁrst
found to modify neuronal responses by Mark Mattson,
who showed that zVAD-fmk increased glutamate-
induced Ca2+ responses in cultured hippocampal neu-
rons, an eﬀect that was attributed to reduced proteolysis
of AMPAR (Mattson, 2000). It was hypothesized that
caspase-mediated cleavage of AMPAR subunits might
prevent excitotoxic necrosis by switching cells to apop-
totic death (Mattson, 2000). More recently, it was shown
that activation of caspase 3 via mitochondria is required
for the internalization of AMPAR at synapses suggesting
that caspase inhibitors might also enhance neuronal sen-
sitivity to glutamate excitotoxicity (Li et al., 2010). A speci-
ﬁc role for necroptosis in neuronal death was revealed by
recent studies, which showed that RIP3-mediated necrop-
tosis is activated in mouse hippocampal neurons after
i.c.v. administration of TNF (Liu et al., 2014) and that
necrostatin1, a speciﬁc inhibitor of necroptosis, reduced
neuron loss in a model of intracerebral hemorrhage (Su
et al., 2015). The importance of caspase activity for neu-
roprotection was also revealed unexpectedly in our own
studies investigating the mechanism of TNFR1 neuropro-
tection in a model for stroke induced by permanent middle
cerebral artery occlusion (pMCAO). In this model,
reduced blood supply induces acute local energy failure
and a core of irreversible necrosis around the infarct
(Dirnagl, 2012). The initial lesion further expands through
delayed death mechanisms involving apoptosis over a
period of days and cell death in this penumbra region
can be limited by inducible mechanisms of neuroprotec-
tion (Dirnagl, 2012). We and others have previously
reported that lesion volumes in TNFR1KO mice were sim-
ilar to wildtype controls 3 and 6 h after pMCAO, but were
signiﬁcantly larger by 24 h, showing that TNFR1 plays an
essential role in limiting infarct progression beyond the
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Taouﬁk et al., 2007). Interestingly, i.c.v. administration
of the pan-caspase inhibitor, zVAD-fmk prior to pMCAO
resulted in signiﬁcantly larger lesions in TNFR1KO com-
pared to controls at 6 h after pMCAO, a time point when
lesion volumes are otherwise similar in the two groups
(Fig. 2) (Petit and Probert, unpublished data). These
results show that pan-caspase inhibition not only fails to
protect mice against apoptotic cell death following
pMCAO, but also reveal an essential role for TNFR1 in
limiting early and massive expansion of lesion volume
under conditions that favor necroptotic cell death. From
the available evidence it is therefore possible that
TNFR1 mediates neuroprotection in the CNS at two
levels; one by gene induction and de novo production of
survival molecules and another, in the absence of ade-
quate survival signals, by caspase 8-dependent apopto-
sis, although formal proof for this remains to be
established.
The reduced physical presence of TNFR1 in a cell,
either by engineered deletion or by natural mutation,
reduces a major pathway of cell death regulation,
exposing cells to unregulated necrosis (necroptosis) by
other death receptors. DR such as TNF-related
apoptosis-inducing ligand (TRAIL) receptor 1 in human
(TRAIL-R1, DR4), TRAIL-R2 in human and mouse
(DR5) and Fas, can also trigger necrosis following
ligand engagement under apoptosis-inhibitory conditions
(Vanden Berghe et al., 2014). TRAIL receptors (Nitsch
et al., 2000; Dorr et al., 2002; Ryan et al., 2004;
Spierings et al., 2004) and low levels of Fas (Rensing-
Ehl et al., 1996) are expressed by neurons, and Fas is
expressed by oligodendrocytes (D’Souza et al., 1996)
and can mediate ligand-induced neuronal death in
response to ischemic injury (Martin-Villalba et al., 1999)
and beta-amyloid toxicity (Uberti et al., 2007). TheseFig. 2. Eﬀects of inhibition of PI3 kinase and caspases upon infarct
volume in wild type and TNFR1 KO mice in a model of focal ischemia.
Mice were pre-treated by i.c.v. administration of the PI3 kinase
inhibitor Ly294002 (320 ng/mouse) or the pan-caspase inhibitor
zVAD.FMK (50 nmol/mouse), prior to permanent middle cerebral
artery occlusion (pMCAO). Mice were sacriﬁced 6 h post-ischemia
and comparison of the mean infarct volumes of each group revealed
signiﬁcant increases in lesion volume in TNFR1KO mice that had
been pretreated with Ly294002 or zVAD.FMK. *P< 0.05,
***P< 0.001 for pairwise comparisons between wild type and
TNFR1KO mice by Student’s t test.receptors contribute to neurotoxicity in various conditions
of neurodegeneration (Aktas et al., 2007; Haase et al.,
2008), including experimental cerebral ischemia–reperfu-
sion injury (Martin-Villalba et al., 1999) and EAE (Aktas
et al., 2005). TRAIL neurotoxicity becomes particularly
relevant in inﬂammatory and autoimmune diseases since
TRAIL ligand is not expressed in the CNS but is
expressed by activated T and B lymphocytes and mono-
cytes which inﬁltrate CNS tissues during disease.
Although TRAIL has been shown to exert immunoregula-
tory eﬀects in the periphery, intracerebral administration
of a soluble TRAIL-neutralizing receptor protected mice
against the clinical symptoms of EAE and immune-
mediated damage to neurons and myelin without alter-
ation of antigen-speciﬁc immune responses in the periph-
ery and CNS (Aktas et al., 2005). Taken together, these
data show that DR of the TNFR superfamily contribute
to the death of neurons and other CNS cells under condi-
tions of neurodegeneration, and their pro-apoptotic
eﬀects are likely to be regulated by TNFR1-induced inhi-
bitors of caspase 8 such as cFLIP, cIAPs etc. It can be
envisioned that DR would trigger elevated levels of apop-
tosis and necroptosis under conditions where TNFR1
function and its anti-apoptotic signaling is reduced or
absent.
Clinical data supporting a role for diminished TNFR1
signaling in the pathogenesis of MS has come from
genetic studies in humans. Genome-wide association
scans for MS susceptibility in large patient cohorts
ﬁrmly identiﬁed a variant in TNFRSF1A, the gene
encoding TNFR1, as a risk factor for MS (De Jager
et al., 2009; Sawcer et al., 2011), but not other autoim-
mune conditions including rheumatoid arthritis (Stahl
et al., 2010), psoriasis (Strange et al., 2010) and
Crohn’s disease (Franke et al., 2010), and as a protec-
tion factor for ankylosing spondylitis (Cortes et al.,
2013). Two independent MS susceptibility alleles were
identiﬁed in this locus: rs1800693 located proximal to
the exon6/intron 6 boundary which results in a risk ‘‘G’’
allele and skipping of exon 6, and rs414584, located in
exon 4, which is associated with an arginine to glutamine
substitution at position 92 (R92Q) (De Jager et al.,
2009). Functional studies showed that the rs1800693
variant encodes a truncated, soluble form of TNFR1 that
lacks the transmembrane and cytoplasmic domains nec-
essary for the proper subcellular localization and signal-
ing of TNFR1 and to associate with full-length TNFR1 to
form receptor heterotrimers with modiﬁed properties
(Gregory et al., 2012). This soluble receptor could still
bind to and neutralize the TNF ligand (Gregory et al.,
2012). Importantly, as noted by these authors, this ﬁnd-
ing parallels the clinical experience with non-selective
TNF inhibitors in MS patients, where exacerbated dis-
ease was observed, and thereby establishes a causal
relationship between diminished TNF signaling and MS
pathogenesis. Based on current knowledge, the TNFR1
variant could contribute to MS by encoding a new natural
TNF antagonist as well as by reducing TNFR1 intracellu-
lar signaling, which, as described above, is important for
inducing protection mechanisms in stressed cells such
as neurons.
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The expression of TNFR2 is highly regulated and found in
few cell types; immune cells particularly regulatory T cells
(Chen et al., 2008), endothelial cells, oligodendrocyte lin-
eage cells (Tchelingerian et al., 1995) and some popula-
tions of neurons (Fig. 1); typically cells that rapidly
increase energy demands during immune responses or
cytoprotection against acute stress stimuli. TNFR2 is a
non-DD-containing receptor; it responds to tmTNF and
solTNF engagement and induces pro-survival signaling
pathways through the direct recruitment of TRAF2
(Rothe et al., 1995) and activation of the
phosphoinositide-3OH kinase (PI3K) and NF-jB path-
ways (Medvedev et al., 1994; Rao et al., 1995). It is
involved in cell proliferation processes (Tartaglia et al.,
1993; Grell et al., 1998) and also potentiates the eﬀects
of TNFR1 in inducing both cell survival and cell death
(Medvedev et al., 1994; Weiss et al., 1997). Functions
of TNFR2 in the CNS were revealed using experimental
models (Table 1). EAE experiments in TNFR2KO mice
showed increased disease severity compared to controls
(Eugster et al., 1999), possibly a result of elevated levels
of circulating solTNF reported in these mice (Erickson
et al., 1994), as well as the absence of important neuro-
protection and repair processes (see below). Seminal
studies by the teams of Ulrich Eisel and Klaus
Pﬁzenmaier show that TNFR2 plays an important role in
neuroprotection against acute excitotoxic and ischemic
injuries. In a model of retinal ischemia–reperfusion injury,
TNFR2KO mice showed increased neurodegeneration
while TNFR1KO showed reduced neuron loss.
Neuroprotection in TNFR1KO mice was associated with
activated Akt/protein kinase B and inhibited by intravitreal
administration of a phosphatidylinositol 3-kinse inhibitor
(Fontaine et al., 2002). TNFR2KO neurons were also
deﬁcient in TNF-mediated protection against glutamate
excitotoxicity, and administration of the phosphatidylinos-
itol 3-kinase inhibitor LY294002 inhibited TNF-mediated
protection in wild-type and TNFR1KO neurons
(Marchetti et al., 2004). Consistent with the neuroprotec-
tive properties of TNFR2, a human TNFR2-speciﬁc
agonistic TNF protected dopaminergic neuronal cells
against oxidative stress in in vitro models for PD
(Fischer et al., 2011). In an independent study, knock-
down of TNFR2 with antisense nucleotides in neuronal
cells increased death in response to hypoxia, amyloid-b,
and TNF (Shen et al., 1997). Further evidence for a pro-
tective function of Akt/protein kinase B was found in the
pMCAO model for cerebral stroke. Here, i.c.v. administra-
tion of Ly294002 prior to pMCAO resulted in signiﬁcantly
larger lesions in TNFR1KO compared to wildtype controls
at 6 h after pMCAO, a time point when lesion volumes are
otherwise similar in the two groups (Fig. 2) (Petit and
Probert, unpublished data).
Together these studies show that TNFR2 signaling
through PKB/Akt and long-term NF-jB activation
represents an important mechanism of neuronal survival
following ischemia–reperfusion injury, glutamate
excitotoxicity, oxidative stress and possibly other deathstimuli, via Akt/protein kinase B and NF-jB signaling
pathways presumably leading to the transcription of
survival and anti-apoptotic target genes. Under
conditions of human tmTNF transgene overexpression
in the mouse CNS, a physiologically regulated human
TNFR2 transgene was further suﬃcient to trigger pro-
inﬂammatory eﬀects characterized by vascular activation
and meningeal and vascular inﬂammation, resulting in
secondary tissue damage (Akassoglou et al., 2003).
Further to a direct neuroprotective eﬀect, TNFR2 might
also reinforce TNFR1-mediated cell-survival and, if
necessary, apoptotic signaling, thereby maximizing neu-
roprotection mediated by tmTNF (see below). Positive
co-operation between TNFR2 and TNFR1 has been
described in cell survival, where responses that are initi-
ated by both receptors via identical pathways through
activation of NF-jB are additive, as well as in cell death
where TNFR1-induced cytotoxicity is potentiated by the
existing stimulation of TNFR2 (Medvedev et al., 1994;
Weiss et al., 1997). Taken together, evidence indicates
that the two TNF receptors might co-operate to mediate
direct neuroprotective eﬀects in the CNS.
TNFR2 mediates additional beneﬁcial activities that
would act to reduce tissue damage and enhance repair
during autoimmune demyelination (Fig. 1). TNFR2 is
expressed at high levels by human and murine
regulatory T cells (Annunziato et al., 2002; Chen et al.,
2008) and mediates their activation and expansion in
mice (Chen et al., 2007), eﬀects that might suppress
CNS-directed autoimmune T cell responses (Fig. 1).
Furthermore, as previously mentioned, TNF and TNFR2
both promote oligodendrocyte precursor cell proliferation
and remyelination in a mouse model of cuprizone-
induced demyelination and remyelination (Arnett et al.,
2001). Insights into the mechanisms that underlie these
eﬀects were provided recently, by the ﬁndings that
TNFR2 protects oligodendrocyte precursor cells against
oxidative stress (Maier et al., 2013) and that astrocyte
TNFR2 mediates oligodendrocyte precursor cell prolifera-
tion and diﬀerentiation via CXCL12 (Patel et al., 2012)
and oligodendrocyte maturation via secretion of leukemia
inhibitory factor (Fischer et al., 2014). Together these
eﬀects might contribute to the maintenance of myelin
sheaths, not only after their damage but also under phys-
iological conditions (Fig. 1).
SOLUBLE TNF
It is already obvious that solTNF, which mediates the pro-
inﬂammatory eﬀects of TNF via TNFR1 signaling, and the
ligand-binding domains of TNFR1 itself, represent major
therapeutic targets for the treatment of chronic
inﬂammatory diseases (see also review by Fischer
et al., 2015). Investigation into the diﬀerential roles of
solTNF and tmTNF in the CNS was ﬁrst made possible
by the development of tmTNF knockin mice in which the
endogenous TNF gene was replaced by a mutant TNF
gene that encodes uncleavable tmTNF (Table 1). In these
mice the initiation of autoimmune pathologies, including
EAE, is severely compromised demonstrating the domi-
nant role of solTNF, and therefore also TNFR1, in the
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Alexopoulou et al., 2006). The development of selective
inhibitors of solTNF and of TNFR1 therefore opened up
an entirely new chapter in the investigation of TNF func-
tion, circumventing the need for permanent gene deletion
or mutation in the germ-line of mice and possible compen-
satory eﬀects by other genes and pathways, and allowing
the therapeutic value of selective solTNF/TNFR1 inhibi-
tion over non-selective TNF inhibition, to be assessed in
the pre-clinical animal models.
Dominant negative TNF mutants (DN-TNFs)
represent a novel class of anti-TNF biologics that
selectively inhibit solTNF while preserving the eﬀects of
tmTNF (Steed et al., 2003; Zalevsky et al., 2007). DN-
TNFs are engineered variants of human solTNF that form
heterotrimers with endogenous (human and murine)
solTNF and thereby prevent solTNF binding to TNFR1.
Importantly, DN-TNFs ameliorate peripheral inﬂammation
as eﬃciently as the non-selective TNF inhibitor etaner-
cept, and unlike etanercept preserve host defense
responses to Listeria monocytogenes (Steed et al.,
2003; Zalevsky et al., 2007). As expected, DN-TNFs reca-
pitulated the results obtained in tmTNF knockin mice. The
eﬀects of systemic or direct CNS administration of
DN-TNFs has now been investigated under diverse
experimental neuroinﬂammatory conditions and revealed
a surprisingly wide range of beneﬁcial eﬀects, as well as
having the advantage of being able to penetrate the
BBB at pharmacologically-relevant levels in normal mice
(Karamita, Tansey & Probert, unpublished results).
Further, in diseases such as EAE and focal cerebral
ischemia, where BBB function is disrupted, the compar-
ison of selective inhibition of solTNF using DN-TNFs with
those of non-selective TNF inhibition using etanercept, an
IgG1 Fc-TNFR2 fusion protein (Murray and Dahl, 1997),
which does not normally penetrate the BBB, has allowed
investigators to gain insights into the diﬀerential functions
of sol and tmTNF in disease pathogenesis. A recently
described BBB-penetrating non-selective inhibitor of
human TNF, based on the extracellular domain of the
TNFR2, which shows similar aﬃnity for TNF as etaner-
cept and provided neuroprotection in a mouse model of
PD (Zhou et al., 2011), should facilitate comparative stud-
ies of solTNF and tmTNF functions in a wider range of
neuroinﬂammatory disorders.
Several biologics that selectively target TNFR1 have
been developed. R1antTNF is a TNFR1-selective
antagonistic mutant TNF that reduced liver injury in a
model of acute hepatitis (Shibata et al., 2008) and amelio-
rated EAE when administered prophylactically, an eﬀect
that was associated with suppression of antigen-speciﬁc
IFN-c- and IL-17-producing T cells (Nomura et al.,
2010). Speciﬁc antagonistic anti-TNFR1 antibodies have
also been developed, including a monovalent domain
anti-mouse TNFR1 antibody (DMS5540) that suppresses
the development of experimentally induced autoimmune
arthritis (McCann et al., 2014); anti-human TNFR1
nanobodies that inhibit TNF-induced liver inﬂammation
in humanized TNFR1 mice (Steeland et al., 2015); a
humanized mouse anti-human TNFR1 antibody
(ATROSAB) (Kontermann et al., 2008) that awaitspre-clinical evaluation. While such reagents are expected
to compare favorably to non-selective TNF inhibitors for
the treatment of peripheral inﬂammatory disorders, and
superior for the preservation of host defense responses
to infections, a limited ability to cross the BBB may limit
their application to CNS inﬂammatory disorders. Proof-
of-principle that TNFR1-speciﬁc antibodies might be rele-
vant for the treatment of MS was provided recently in an
EAE model, where administration of an anti-TNFR1 anti-
body in prophylactic and therapeutic protocols amelio-
rated disease (Williams et al., 2014).
Neuroinﬂammation is a hallmark of all CNS
neurodegenerative diseases. In PD solTNF and
solTNFR1 levels are increased in cerebrospinal ﬂuid
and tissues of patients (Boka et al., 1994; Mogi et al.,
1994; Hirsch and Hunot, 2009). The cause of neuronal
loss in PD is not known but non-cell autonomous mecha-
nisms, mediated by activated glia and peripheral immune
cells including CD4 and CD8 lymphocytes, are thought to
be important. A positive feedback mechanism whereby
chronic neuroinﬂammation causes oxidative damage
and death of dopaminergic neurons, and neurodegenera-
tion in turn perpetuates inﬂammation, is likely to underlie
the pathogenesis of this disease. Studies with DN-TNFs
in experimental models for PD allowed Malu Tansey
and her group to clarify the somewhat inconclusive results
obtained using TNFR-deﬁcient mice (see above). They
demonstrated that solTNF, and therefore TNFR1, plays
a critical role in mediating the death of dopamine neurons
in vitro and in vivo, an eﬀect that was associated with
potentiation of microglia activation. The intranigral deliv-
ery of a PEGylated DN-TNF protein named XENP345,
or a lentivirus encoding the non-PEGylated protein,
reduced neuroinﬂammation and loss of substantia nigra
dopamine neurons in endotoxin (LPS) and neurotoxin
(6-hydroxydopamine, 6-OHDA) rat models for PD
(McCoy et al., 2006; McCoy and Tansey, 2008).
XENP345 also attenuated dopamine neuron toxicity in
mixed neuron/glia cultures induced by LPS or 6-OHDA
(McCoy et al., 2006). These results demonstrate that
solTNF is neurotoxic to dopamine neurons and that selec-
tive inhibition of solTNF is neuroprotective. Importantly,
this group also recently showed that peripheral s.c.
administration of a similar DN-TNF, XPro1595, was suﬃ-
cient to attenuate neuroinﬂammation and dopamine neu-
ron loss in the 6-OHDA model (Barnum et al., 2014).
Although it still remains to be established whether neu-
roinﬂammation is primary or secondary to dopaminergic
neuron loss in PD, these studies clearly demonstrate a
pathogenic role for solTNF and the therapeutic relevance
of DN-TNF biologics for treatment in PD.
In AD too, experimental and clinical evidence suggest
that neuroinﬂammation plays a key role in disease
pathogenesis (McAlpine and Tansey, 2008). Activated
microglia are closely associated with amyloid plaques in
AD brains and elevated levels of pro-inﬂammatory cytoki-
nes, including solTNF, were reported in sera (Fillit et al.,
1991; Paganelli et al., 2002). On the other hand, solTNF
was one of the proteins selectively reduced in the plasma
of patients with mild cognitive impairment leading to AD
as well as patients with established AD (Ray et al.,
14 L. Probert / Neuroscience 302 (2015) 2–222007). Although apparently conﬂicting, these ﬁndings
clearly indicate there is a systemic dysregulation of
peripheral immune responses, and of TNF production,
in this disease. Experimental evidence for disease-
promoting eﬀects of neuroinﬂammation and
solTNF/TNFR1 signaling come from studies in transgenic
disease models. In the APP23 model, which expresses a
disease-associated mutant human b amyloid precursor
protein (APP) selectively in neurons and results in exten-
sive amyloid b (Ab) plaque formation (Sturchler-Pierrat
et al., 1997), absence of TNFR1 signaling inhibited the
pathological hallmarks of AD: microglia activation, pro-
duction of b-secretase 1(BACE1), an enzyme involved
in processing of APP, generation of Ab, Ab plaque forma-
tion, neuronal loss, and prevented associated learning
and memory defects (He et al., 2007). Similar beneﬁcial
eﬀects were seen by the Tansey lab with TNFR1 deﬁ-
ciency or solTNF inhibition in a triple transgenic mouse
model of AD (3xTG-AD), which expresses three diﬀerent
disease-associated genes (Oddo et al., 2003). Here tran-
sient inhibition of solTNF prior to plaque formation by infu-
sion of XENP345 into the hippocampus, or persistent
inhibition by i.c.v. injection of a lentivirus encoding DN-
TNF, prevented the acceleration of AD-like pathology by
systemically administered LPS, reducing both microglial
activation and accumulation of APP in the brain
(McAlpine et al., 2009). Interestingly, a pilot open-label
clinical trial in which AD patients received perispinal infu-
sion of etanercept or placebo claimed that patients receiv-
ing the non-selective TNF inhibitor showed improvement
of cognitive performance compared to controls indicating
the therapeutic relevance of TNF inhibition in AD
(Tobinick and Gross, 2008). It is not immediately clear
how perispinal etanercept exerts its beneﬁcial eﬀects in
AD since it does not penetrate the BBB. Nevertheless,
the clinical results with TNF inhibitors are promising and
need to be conﬁrmed in further trials.
Neuroinﬂammation is also a feature of Huntington’s
disease (HD), which is caused by an expanded CAG
repeat in exon 1 of the huntingtin gene. TNF is
increased in the plasma and brain tissues of HD
patients and mouse models for this disease (Bjorkqvist
et al., 2008). Intracerebroventricular infusion of
XPro1595 in a transgenic mouse model for HD (R6/2)
reduced neurotoxicity and glial reactivity and improved
motor function, with signiﬁcant beneﬁcial eﬀects being
obtained also by systemic administration of XPro1595
(Hsiao et al., 2014). The ﬁnding that XPro1595 reduced
the inﬂammatory responses of astrocyte-enriched cul-
tures derived from R6/2 transgenic mice and induced
pluripotent stem cells from HD patients in response to
LPS and cytokines suggested that the beneﬁcial eﬀects
of solTNF inhibition in HD models are at least partially
due to reduction of neuroinﬂammation (Hsiao et al.,
2014).TRANSMEMBRANE TNF
Information concerning the role of tmTNF in the CNS
under physiological and disease conditions is currently
much more limited, mainly because of theimpermeability of the BBB to biologics that block tmTNF
function such as antibodies and receptor constructs.
Further to the genetic studies in tmTNF knockin mice
already described, the comparative roles of solTNF and
tmTNF have been studied in EAE using DN-TNF
(Brambilla et al., 2011; Taouﬁk et al., 2011). In EAE,
selective inhibition of solTNF with XPro1595 improved
clinical outcome, showing that solTNF promotes disease,
whereas non-selective inhibition of both solTNF and
tmTNF with etanercept did not result in protection, indicat-
ing that tmTNF has strong beneﬁcial eﬀects. The thera-
peutic eﬀects of DN-TNF were associated with reduced
neuroinﬂammation, demyelination and axon damage,
increased remyelination accompanied by increased num-
bers of NG2+ oligodendrocyte precursors, perhaps due
to preferential TNFR2 functioning (see above), and were
dependent upon neuronal NF-jB signaling (Brambilla
et al., 2011; Taouﬁk et al., 2011). Taken together with
the ﬁndings that TNFR1 is localized in neurons, oligoden-
drocytes, astrocytes and macrophages/microglia, that
TNFR2 is localized in mature oligodendrocytes, NG2+
oligodendrocyte precursor cells, astrocytes and macro-
phages/microglia in EAE mice and MS patients, and that
tmTNF is required for neuroprotection in astrocyte-neuron
co-cultures (Papazian and Probert, unpublished data),
these data support an essential role for tmTNF in the pro-
tection of neurons and myelin as well as for remyelination
in demyelinating CNS diseases.
DN-TNF was also beneﬁcial in a mouse model of focal
cerebral ischemia (pMCAO). In this model of acute CNS
injury, the peripheral administration of two diﬀerent
inhibitors, XPro1595 and etanercept, had similar eﬀects.
Both XPro1595 and etanercept improved functional
outcome without altering lesion volume, reducing
granulocyte inﬁltration into the CNS and microglia
activation, indicating that solTNF, which is inhibited by
both treatments, plays a dominant role in promoting
harmful immune responses from the periphery in this
model (Clausen et al., 2014). By contrast, in a spinal cord
injury model in mice, peripheral administration of TNF
inhibitors had no detectable eﬀect on improving locomotor
performance after injury, while central administration of
XPro1595, but not etanercept, resulted in improved loco-
motor function, decreased anxiety-related behavior and
reduced tissue damage. Importantly, the protective
eﬀects of inhibiting pro-inﬂammatory solTNF function
were associated with upregulated TNFR2 expression in
the spinal cord, thereby facilitating tmTNF/TNFR2-
mediated neuroprotection and repair functions (Novrup
et al., 2014).FUTURE PERSPECTIVES
Compelling evidence now shows that TNF-TNFR
signaling in the CNS is much more than a
pathogenically relevant mechanism that underlies
chronic inﬂammation in neurodegenerative disease. The
multiplicity of TNF’s eﬀects in the CNS range between
essential, desirable and deleterious (summarized in
Table 2) and although there is much yet to be learned
about its roles in the physiology and pathophysiology of
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matrix for a model upon which new ﬁndings can be
critically evaluated and safer therapeutic strategies can
be rationally designed. The weight of evidence
incriminates solTNF and TNFR1 signaling in mediating
the deleterious pro-inﬂammatory eﬀects that promote
autoimmune and neurodegenerative diseases and
indicates that that selective targeting of these molecules
with reagents such as DN TNF and anti-TNFR1
antibodies, for therapeutic purposes, would eﬀectively
reduce pathology while respecting important
contributions of tmTNF, TNFR2 and intracellular TNFR1
in host defense, neuroprotection and brain repair
mechanisms. A potential caveat to such an approach in
the development of therapeutic targeting approaches for
CNS, would be careful consideration of the eﬀects of
solTNF, and therefore probably TNFR1, in the
regulation of neuronal activity through mechanisms such
as synaptic scaling and gliotransmission, although such
mechanisms likely take place in the sheltered
environment of the synaptic cleft in the intact brain and
therefore might not be susceptible to molecular inhibitors.
Our understanding of TNF function in the brain has
currently gained fresh momentum alongside advances
in knowledge concerning the roles of microglia, the main
cellular source of TNF in the CNS, under physiological
and pathophysiological conditions. Microglia are now
recognized to perform important homeostatic functions
in the normal adult brain that stand in sharp contrast to
conventional wisdom concerning their roles in host
defense, as sensors of injury and infection and initiators
of innate immune responses, as well as in triggering
tissue inﬂammation and secondary tissue damage. The
availability of improved genetic tools in mice, notably
microglia-speciﬁc ﬂuorescent reporters for use with
in vivo 2-photon microscopy, and mice in which genes
can be deleted or re-expressed selectively in microglia,
has been instrumental for revealing previously
unsuspected roles of microglia in synaptic pruning and
the maturation of neuronal circuitry during development
(Paolicelli et al., 2011; Schafer et al., 2012), and in the
adult brain (Davalos et al., 2005; Nimmerjahn et al.,
2005) where they directly contact neuronal synapses
(Wake et al., 2009; Tremblay et al., 2010) and regulate
synaptic activity plasticity, learning and memory
(Li et al., 2012; Ji et al., 2013; Kyrargyri et al., 2015),.
The striking parallelism between the range of ‘‘beneﬁcial’’
and ‘‘deleterious’’ functions of microglia and of their main
products, tumor necrosis factor (TNF), interleukin-1b
(IL-1b) and nitric oxide (NO) in the CNS, promises that
the complex network of TNF ligand/receptor signaling in
the CNS will soon be reconciled at a cellular level with
functions of microglia, and eventually with other cells that
produce and respond to this cytokine, including astro-
cytes, oligodendrocyte precursor cells and neurons.
Interestingly to date, microglia-derived IL-1b has been
implicated in the regulation of synaptic plasticity and cog-
nitive function in the brain under physiological conditions
(Rogers et al., 2011; Kyrargyri et al., 2015) and it is prob-
able that corresponding data for TNF will emerge. In the
case of microglia and TNF, important milestones will beto deﬁne the mechanisms responsible for switching micro-
glia from normal physiologically-important cells into
chronically-activated, disease-promoting cells under con-
ditions of CNS neurodegeneration and to determine
whether blockade of activated microglia products, such
as solTNF, can reverse this process and provide a treat-
ment for chronic neurodegenerative diseases such as AD,
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